ABL1 and acute lymphoblastic leukemia: A rate of BCR–ABL1 kinase domain (TKD) mutations of >80% has been reported in (adult) patients with Ph+ ALL at relapse (165–167), with the most common mutations being T315I, Y253H, and E255K/V (42, 168).